Plain-English translation of NCT06619613 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new medication called CM383 to see if it is safe and how it works in people with early Alzheimer's disease or mild memory loss related to Alzheimer's. Researchers will give some participants the medication through an IV infusion and others a placebo (inactive treatment) to compare how well the medication is tolerated and what happens in the body. The study will gradually increase the dose to find the safest and most effective level of this treatment.
Alzheimer's disease is a progressive condition that affects memory and thinking, and there is a need for new treatments that can help slow or stop its progression. This trial is exploring whether this medication might be a helpful option for people in the early stages of the disease.
You likely qualify if…
You likely don't qualify if…
If you join this study, you would receive the medication (or placebo) through an IV infusion at a clinic or hospital. The study starts with a low dose and gradually increases it in different groups to test safety and see how your body responds. You would have visits for check-ups, blood tests, and cognitive assessments to monitor how you're doing and how the medication affects you over time.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China